Metronomic capecitabine as second-line treatment in hepatocellular carcinoma after sorafenib failure
- 1 June 2015
- journal article
- research article
- Published by Elsevier BV in Digestive and Liver Disease
- Vol. 47 (6), 518-522
- https://doi.org/10.1016/j.dld.2015.03.010
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- A systematic literature analysis of correlative studies in low-dose metronomic chemotherapy trialsBiomarkers in Medicine, 2014
- Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial DesignClinical Cancer Research, 2014
- Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapyJournal of Hepatology, 2013
- Low-dose metronomic chemotherapy: A systematic literature analysisEuropean Journal of Cancer, 2013
- Postprogression survival of patients with advanced hepatocellular carcinoma: Rationale for second-line trial designJournal of Hepatology, 2013
- EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinomaJournal of Hepatology, 2012
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialThe Lancet Oncology, 2008
- Sorafenib in Advanced Hepatocellular CarcinomaThe New England Journal of Medicine, 2008
- Capecitabine: A reviewClinical Therapeutics, 2005
- The anti-angiogenic basis of metronomic chemotherapyNature Reviews Cancer, 2004